Lynovex oral (cysteamine oral) / NovaBiotics - LARVOL DELTA

NovaBiotics to Present New Data at Upcoming North American Cystic Fibrosis Conference (PRNewswire) - "NovaBiotics...announces that they will present two posters highlighting new preclinical data on cysteamine at the North American Cystic Fibrosis Conference taking place virtually from November 2-5, 2021....'We look forward to the presentation of these new compelling preclinical data as they further elucidate the antimicrobial mechanism of action of cysteamine which is the API of our NM001 candidate therapies for CF. These new findings also support the positive clinical data we have generated to date with oral NM001 in two Phase 2 studies in CF patients and our preclinical studies of an inhaled form of NM001...'"

Preclinical • Cystic Fibrosis

Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics (PMLive) - "Lynovex® for cystic fibrosis (CF)...is now registration trial-ready in oral form (for infectious pulmonary exacerbations of CF), and phase 1 ready in inhaled form (for the long-term maintenance of respiratory function in CF patients). The next clinical trials for both of the Lynovex® product candidates could commence as soon as H2 2021."

New P1 trial • New trial • Cystic Fibrosis